ARWR Stock Risk & Deep Value Analysis
Arrowhead Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ARWR Stock
We analyzed Arrowhead Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARWR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is ARWR Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for ARWR?
- ⚠
Regulatory delays or outright rejection for ARO-AAT by FDA/EMA.
- ⚠
Clinical trial failures or safety concerns for other key pipeline assets.
- ⚠
Stronger-than-expected competition in AATD or other target indications.
- ⚠
Negative results from ongoing trials for partnered assets impacting future milestone payments.
Unlock ARWR Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Arrowhead Pharmaceuticals Inc (ARWR) Do?
Market Cap
$9.19B
Sector
Healthcare
Industry
Biotechnology
Employees
711
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Visit Arrowhead Pharmaceuticals Inc WebsiteIs ARWR Stock Undervalued?
Unlock the full AI analysis for ARWR
Get the complete DVR score, risk analysis, and more
Does ARWR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The proprietary TRiM platform and its associated intellectual property offer durable protection, making it difficult for competitors to replicate the delivery efficiency and targeting specificity. Successive clinical approvals will further solidify this moat.
Moat Erosion Risks
- •Patent expiry for key assets in the long term (10+ years).
- •Emergence of a superior gene editing or gene therapy technology that bypasses RNAi.
- •Intense competition in specific disease indications where Arrowhead operates.
ARWR Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ARWR Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 (fiscal Q1 2026) Earnings Call: Expected early May 2026, focus on ARO-AAT regulatory update.
- •ARO-AAT (fazirsiran) Regulatory Submission (US/EU): Expected Q2-Q3 2026.
- •Update on partnered programs (ARO-APOC3, ARO-ANG3) from J&J: Clinical trial progress or data readouts in H1 2026.
Medium-Term (6-18 months)
- •ARO-AAT (fazirsiran) Regulatory Approval (US/EU): Expected late Q4 2026 / early Q1 2027.
- •Initial Commercialization Strategy & Market Access Details for ARO-AAT: H1 2027.
- •Phase 2/3 Data for J&J partnered programs (ARO-APOC3, ARO-ANG3): Late 2026 / H1 2027.
Long-Term (18+ months)
- •Expansion of TRiM platform into new disease areas beyond liver and genetic disorders.
- •Multiple product launches across various indications, establishing market leadership in RNAi.
- •Potential for additional strategic partnerships for pipeline assets.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ARWR?
- ✓
Successful and timely regulatory approval for ARO-AAT in major markets (US/EU).
- ✓
Positive clinical readouts and advancement of partnered pipeline assets.
- ✓
Successful commercial launch and ramp-up of ARO-AAT sales post-approval.
- ✓
Maintainance of a strong cash position and disciplined capital allocation.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ARWR (Arrowhead Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
